17 alpha-hydroxylase deficiency differential diagnosis: Difference between revisions
No edit summary |
|||
Line 246: | Line 246: | ||
[[Turner syndrome|45 XO]] | [[Turner syndrome|45 XO]] | ||
|} | |} | ||
===Other differentials=== | |||
17 alpha-hydroxylase deficiency must be differentiated from diseases that cause [[ambiguous genitalia]]:<ref name="pmid17875484">{{cite journal |vauthors=Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT |title=Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development |journal=Best Pract. Res. Clin. Endocrinol. Metab. |volume=21 |issue=3 |pages=351–65 |year=2007 |pmid=17875484 |doi=10.1016/j.beem.2007.06.003 |url=}}</ref><ref name="pmid10857554">{{cite journal |vauthors=White PC, Speiser PW |title=Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |journal=Endocr. Rev. |volume=21 |issue=3 |pages=245–91 |year=2000 |pmid=10857554 |doi=10.1210/edrv.21.3.0398 |url=}}</ref> | |||
{| class="wikitable" | |||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease name | |||
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Steroid status | |||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Important clinical findings | |||
|- | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Increased | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Decreased | |||
|- | |||
|[[21-hydroxylase deficiency|Classic type of 21-hydroxylase deficiency]] | |||
| | |||
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | |||
* [[Progesterone]] | |||
* [[Androstenedione]] | |||
* [[DHEA]] | |||
| | |||
* [[Aldosterone]] | |||
* [[Corticosterone]] (salt-wasting) | |||
* [[Cortisol]] ([[virilization]]) | |||
| | |||
* [[Ambiguous genitalia]] in female | |||
* [[Virilization]] in female | |||
* Salt-wasting | |||
* [[Hypotension]] and [[hyperkalemia]] | |||
|- | |||
|[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]] | |||
| | |||
* [[Deoxycorticosterone]] | |||
* 11-Deoxy-[[cortisol]] | |||
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] (mild elevation) | |||
| | |||
* [[Cortisol]] | |||
* [[Corticosterone]] | |||
* [[Aldosterone]] | |||
| | |||
* [[Ambiguous genitalia]] in female | |||
* [[Hypertension]] and [[hypokalemia]] | |||
* [[Virilization]] | |||
|- | |||
|[[17 alpha-hydroxylase deficiency|17-α hydroxylase deficiency]] | |||
| | |||
* [[Deoxycorticosterone]] | |||
* [[Corticosterone]] | |||
* [[Progesterone]] | |||
| | |||
* [[Cortisol]] | |||
* [[Aldosterone]] | |||
| | |||
* [[Ambiguous genitalia]] in male | |||
* [[Hypertension]] | |||
* [[Primary amenorrhea]] | |||
* Absence of [[secondary sexual characteristics]] | |||
* Minimal [[body hair]] | |||
|- | |||
|[[3 beta-hydroxysteroid dehydrogenase deficiency]] | |||
| | |||
* [[Dehydroepiandrosterone]] | |||
* [[17-hydroxypregnenolone]] | |||
* [[Pregnenolone]] | |||
| | |||
* [[Cortisol]] | |||
* [[Aldosterone]] | |||
| | |||
* [[Vomiting]], [[volume depletion]], [[hyponatremia]], and [[hyperkalemia]] | |||
* 46-XY infants often show [[undervirilization]], due to a block in [[testosterone]] synthesis | |||
|- | |||
| Gestational [[hyperandrogenism]] | |||
| colspan="2" | | |||
* Maternal serum [[androgen]] concentrations (usually [[testosterone]] and [[androstenedione]]) are high | |||
* If [[virilization]] is caused by exogenous hormone administration, the values may be low because the offending hormone is usually a synthetic [[steroid]] not measured in assays for [[testosterone]] or other [[androgens]] | |||
| | |||
* [[Androgen]] excess in mother | |||
* History of [[androgen]] containing [[medication]] consumption during [[pregnancy]] in mother | |||
* [[Virilization]] in a 46,XX individual with normal female internal anatomy | |||
* Causes include maternal [[luteoma]] or theca-[[lutein]] [[cysts]], and [[placental]] [[aromatase]] enzyme deficiency | |||
|} | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} |
Revision as of 18:16, 28 August 2017
17 alpha-hydroxylase deficiency Microchapters |
Differentiating 17 alpha-hydroxylase deficiency from other Diseases |
Diagnosis |
Treatment |
Case Studies |
17 alpha-hydroxylase deficiency differential diagnosis On the Web |
American Roentgen Ray Society Images of 17 alpha-hydroxylase deficiency differential diagnosis |
FDA on 17 alpha-hydroxylase deficiency differential diagnosis |
CDC on 17 alpha-hydroxylase deficiency differential diagnosis |
17 alpha-hydroxylase deficiency differential diagnosis in the news |
Blogs on 17 alpha-hydroxylase deficiency differential diagnosis |
Risk calculators and risk factors for 17 alpha-hydroxylase deficiency differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Overview
17 alpha-hydroxylase deficiency must be differentiated from diseases with primary amenorrhea and female external genitalia. Some of these causes include Pregnancy, androgen insensitivity syndrome, 3beta-hydroxysteroid dehydrogenase type 2 deficiency, 17-alpha-hydroxylase deficiency, gonadal dysgenesis, testicular regression syndrome, LH receptor defects, 5-alpha-reductase type 2 deficiency, mullerian agenesis, primary ovarian insufficiency, hypogonadotropic hypogonadism and turner syndrome.
Differentiating 17 alpha-hydroxylase deficiency from other Diseases
17 alpha-hydroxylase deficiency must be differentiated from diseases with primary amenorrhea and female external genitalia. Some of these causes include Pregnancy, androgen insensitivity syndrome, 3beta-hydroxysteroid dehydrogenase type 2 deficiency, 17-alpha-hydroxylase deficiency, gonadal dysgenesis, testicular regression syndrome, LH receptor defects, 5-alpha-reductase type 2 deficiency, mullerian agenesis, primary ovarian insufficiency, hypogonadotropic hypogonadism and turner syndrome.[1][2][3][4][5][6][7][8]
Disease name | Cause | Differentiating | ||||||
---|---|---|---|---|---|---|---|---|
Findings | Uterus | Breast development | Testosterone | LH | FSH | Karyotyping | ||
3-beta-hydroxysteroid dehydrogenase type 2 deficiency |
|
Yes in female |
Yes in female |
Low |
Normal |
Normal |
||
17-alpha-hydroxylase deficiency |
|
No |
No |
Low |
Normal |
Normal |
||
Gonadal dysgenesis |
|
|
Yes |
Yes |
Low |
High |
High |
|
Testicular regression syndrome |
|
|
No |
No |
Low |
High |
High |
|
LH receptor defects |
|
No |
No |
Low |
High |
High |
||
5-alpha-reductase type 2 deficiency |
|
No |
No |
Normal male range |
High to normal |
High to normal |
||
Androgen insensitivity syndrome |
|
|
No |
Yes |
Normal male range |
Normal |
Normal |
|
Mullerian agenesis |
|
No |
Yes |
Normal female range |
Normal |
Normal |
||
Primary ovarian insufficiency |
|
|
Yes |
Yes |
Normal female range |
High |
High |
|
Hypogonadotropic hypogonadism |
|
|
Yes |
No |
Normal female range |
Low |
Normal |
|
|
|
Yes |
Yes |
Normal female range |
High |
High |
Other differentials
17 alpha-hydroxylase deficiency must be differentiated from diseases that cause ambiguous genitalia:[9][10]
Disease name | Steroid status | Important clinical findings | |
---|---|---|---|
Increased | Decreased | ||
Classic type of 21-hydroxylase deficiency |
|
| |
11-β hydroxylase deficiency |
|
| |
17-α hydroxylase deficiency |
| ||
3 beta-hydroxysteroid dehydrogenase deficiency |
| ||
Gestational hyperandrogenism |
|
|
References
- ↑ Maimoun L, Philibert P, Cammas B, Audran F, Bouchard P, Fenichel P, Cartigny M, Pienkowski C, Polak M, Skordis N, Mazen I, Ocal G, Berberoglu M, Reynaud R, Baumann C, Cabrol S, Simon D, Kayemba-Kay's K, De Kerdanet M, Kurtz F, Leheup B, Heinrichs C, Tenoutasse S, Van Vliet G, Grüters A, Eunice M, Ammini AC, Hafez M, Hochberg Z, Einaudi S, Al Mawlawi H, Nuñez CJ, Servant N, Lumbroso S, Paris F, Sultan C (2011). "Phenotypical, biological, and molecular heterogeneity of 5α-reductase deficiency: an extensive international experience of 55 patients". J. Clin. Endocrinol. Metab. 96 (2): 296–307. doi:10.1210/jc.2010-1024. PMID 21147889.
- ↑ Moreira AC, Leal AM, Castro M (1990). "Characterization of adrenocorticotropin secretion in a patient with 17 alpha-hydroxylase deficiency". J. Clin. Endocrinol. Metab. 71 (1): 86–91. doi:10.1210/jcem-71-1-86. PMID 2164530.
- ↑ Heremans GF, Moolenaar AJ, van Gelderen HH (1976). "Female phenotype in a male child due to 17-alpha-hydroxylase deficiency". Arch. Dis. Child. 51 (9): 721–3. PMC 1546244. PMID 999330.
- ↑ Biglieri EG (1979). "Mechanisms establishing the mineralocorticoid hormone patterns in the 17 alpha-hydroxylase deficiency syndrome". J. Steroid Biochem. 11 (1B): 653–7. PMID 226795.
- ↑ Saenger P (1996). "Turner's syndrome". N. Engl. J. Med. 335 (23): 1749–54. doi:10.1056/NEJM199612053352307. PMID 8929268.
- ↑ Bastian C, Muller JB, Lortat-Jacob S, Nihoul-Fékété C, Bignon-Topalovic J, McElreavey K, Bashamboo A, Brauner R (2015). "Genetic mutations and somatic anomalies in association with 46,XY gonadal dysgenesis". Fertil. Steril. 103 (5): 1297–304. doi:10.1016/j.fertnstert.2015.01.043. PMID 25813279.
- ↑ Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE (1974). "Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism". Science. 186 (4170): 1213–5. PMID 4432067.
- ↑ Schnitzer JJ, Donahoe PK (2001). "Surgical treatment of congenital adrenal hyperplasia". Endocrinol. Metab. Clin. North Am. 30 (1): 137–54. PMID 11344932.
- ↑ Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT (2007). "Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development". Best Pract. Res. Clin. Endocrinol. Metab. 21 (3): 351–65. doi:10.1016/j.beem.2007.06.003. PMID 17875484.
- ↑ White PC, Speiser PW (2000). "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Endocr. Rev. 21 (3): 245–91. doi:10.1210/edrv.21.3.0398. PMID 10857554.